Paper36917758
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M and 22 others. J Clin Oncol, 2023. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Papers, record 36917758. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36917758
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Intraductal, Noninfiltrating | Major topic |
| Breast Neoplasms | Major topic |
| Carcinoma in Situ | Major topic |
| Female | |
| Humans | |
| Tamoxifen | |
| Follow-Up Studies | |
| Antineoplastic Agents, Hormonal | |
| Neoplasm Recurrence, Local |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01357772 | Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up | Results | Yes |
Source ClinicalTrials.gov
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42693657 | Discovery of ERα-Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y537S Mutant Inhibition. | Chem Biol Drug Des | 2026 | https://conductscience.org/library/papers/42693657 | PubMed |
| 42684505 | Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42684505 | PubMed |
| 42233150 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026. | Breast Care (Basel) | 2026 | https://conductscience.org/library/papers/42233150 | PubMed |
| 42114785 | Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials. | Int J Radiat Oncol Biol Phys | 2026 | https://conductscience.org/library/papers/42114785 | PubMed |
| 42041742 | Reconsidering the Interpretation of "Recurrence-Free Survival" After Mastectomy for DCIS. Comment on Sae-sim et al. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy. Curr. Oncol. 2026, 33, 89. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42041742 | PubMed |
| 42001127 | A pilot study of a behavior-change intervention for preventive therapy among women at high risk for invasive breast cancer. | BMC Med Inform Decis Mak | 2026 | https://conductscience.org/library/papers/42001127 | PubMed |
| 41927957 | Reply to "Beyond Uptake Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk," by Hu, Zhiping et al. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41927957 | PubMed |
| 41918186 | Clinical Outcomes of Lobular Carcinoma In Situ: Risk of Invasive Cancer Development. | J Breast Cancer | 2026 | https://conductscience.org/library/papers/41918186 | PubMed |
| 41744831 | High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41744831 | PubMed |
| 41667737 | Low-dose tamoxifen ameliorates ovariectomy-induced metabolic and immune dysfunction. | Geroscience | 2026 | https://conductscience.org/library/papers/41667737 | PubMed |
| 41654661 | Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41654661 | PubMed |
| 41619719 | BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk. | Gynecol Oncol | 2026 | https://conductscience.org/library/papers/41619719 | PubMed |
| 41572119 | Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy Uptake. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41572119 | PubMed |
| 41510186 | Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41510186 | PubMed |
| 41495021 | Signaling pathways and targeted interventions for precancers. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41495021 | PubMed |
| 41493489 | RISE UP for breast cancer 2024: conference highlights & takeaways. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41493489 | PubMed |
| 41468356 | Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ. | Cancer Prev Res (Phila) | 2026 | https://conductscience.org/library/papers/41468356 | PubMed |
| 41300964 | Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41300964 | PubMed |
| 41175180 | Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41175180 | PubMed |
| 41002088 | [Systemic treatment of breast cancer: professional guideline]. | Magy Onkol | 2025 | https://conductscience.org/library/papers/41002088 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TAMOXIFEN | CHEMBL83 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL83 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36917758
GET https://conductscience.org/api/papers/v1/36917758/authors?page=2